The report "Cannabidiol Market Size by Source (Hemp, Marijuana), by Distribution Channel (B2B, B2C), End-use (Medical, Personal Use), Region (North America, Europe, Asia Pacific, and Rest of the World) - Global Forecast to 2027", is projected to reach USD 11.9 billion by 2027 from USD 5.4 Billion in 2022, at a CAGR of 17.1% during the forecast period
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/cannabidiol-market-94451002.html
Factors such as the increased acceptance and use of cannabidiol because of regulatory approvals coupled with increased demand for health and wellness applications due to its therapeutic characteristics will drive the market growth of cannabidiol over the forecast period.
The marijuana segment accounted for the largest share of the cannabidiol market in 2021.
Based on source, the cannabidiol market is segmented into marijuana and hemp. In 2021, the marijuana segment accounted for the largest share of the cannabidiol market. The key factors driving the growth of the segment include rising acceptability of refined cannabidiol products as well as the rising legalization of marijuana and goods derived from it for a variety of medical uses. The high efficacy of cannabidiol derived from marijuana is another important reason driving the segment's rise.
North America to command the largest share of the cannabidiol market in 2021
Based on region, the cannabidiol market is segmented into North America, Europe, the Asia Pacific, and Rest of the World. North America accounted for the largest share of the cannabidiol market in 2021. Some of the key factors attributable for the largest market share are the presence of a sizable population of health-conscious individuals, the growing acceptance of cannabidiol based products, the presence of key manufacturers, and the approval of the U.S. Farm Bill in 2020.
Prominent players in the cannabidiol market include Canopy Growth Corporation (Canada), Aphria, Inc. (US), Aurora Cannabis (Canada), Maricann, Inc. (Wayland Group Corporation) (Canada), Tilray (US), GW Pharmaceuticals Plc (UK), Abcann Medicinals, Inc. (US), Organigram Holding Inc. (Canada), Tikun Olam (Israel), The Cronos Group (Canada), Endoca (US), Isodiol International, Inc. (Canda), Medical Marijuana, Inc. (US), Cannoid, LLC (US), Elixinol (Australia), Folium Biosciences (US), Nuleaf Naturals, LLC (US), and Pharmahemp D.O.O. (Slovania).
About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
sales@marketsandmarkets.com